SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Interim Management Statement

8 Nov 2013 07:00

RNS Number : 5148S
Rentokil Initial PLC
08 November 2013
Β 

ο»Ώ

Β 

Β 

RENTOKIL INITIAL PLC (RTO)

INTERIM MANAGEMENT STATEMENT

8 November 2013

Β 

Β (Β£m)

Q3 2013

Growth

YTD 2013

Growth

AER

AER

CER

AER

AER

CER

Revenue

585.1

6.2%

3.8%

1,751.4

5.6%

3.7%

Adjusted operating profit1

70.8

6.1%

3.0%

183.4

6.9%

4.3%

Adjusted profit before tax2

56.0

1.1%

(1.8%)

143.6

2.3%

0.4%

Profit before tax

43.6

6.1%

3.1%

95.5

(9.0%)

(10.4%)

Operating cash flow3

50.4

36.6

Β 

Commenting on the group's Q3 trading update, Andy Ransom, new Chief Executive Officer of Rentokil Initial plc, said:

Β 

"I am encouraged by our core businesses' improvement in organic revenue growth in Q3, despite the difficult trading conditions in Europe and the Netherlands in particular. We expect trading conditions and business performance to remain largely unchanged over the remainder of the year.

Β 

"As we approach the end of a major restructuring and investment programme, my focus is now on converting this into improved profitability and cash generation. Our overheads are coming down, our businesses are becoming more efficient and during next year our restructuring costs and capex will also reduce. I will provide further detail on my plans to deliver sustainable revenue and profit growth and increased free cash flow at the year-end results."

Β 

Revenue (at CER)

Β 

Revenue grew by 3.8%, largely reflecting the contribution from the Western acquisition with North America up 45.7% (Β£29.0m). Organic revenue in the core business rose by 1.0%, despite ongoing challenging trading conditions in Europe, reflecting solid performances from all geographies in the West region, as well as in France and Asia.

Β 

Revenue in IF declined by 5.9% due to the planned withdrawal from single-site contracts in the UK, lower job revenues in technical services and delays in the award of anticipated new contracts over the summer. Β£25m of new business was however secured at the end of Q3.

Β 

Profit (at CER)

Β 

Adjusted operating profit increased by 3.0%. Profit in the West region grew by 14.5% (Β£4.3m), again reflecting the impact of Western with North America profits up 26.5% (Β£2.6m), supported by 15.7% (Β£1.4m) profit growth in the UK & Ireland.

Β 

Asia continues to perform well, with profits up by 23.5% (Β£0.4m) on the prior year on continued strong revenue growth.

Β 

Profit in the East region declined 3.1% (Β£1.5m), driven by weak performance in Benelux (the Netherlands in particular) but also softening in France and Germany. Pricing pressure in the Workwear category continues to impact margins.

Β 

Profit in IF fell by 20.3% (Β£1.4m), reflecting the revenue decline described above as well as pricing pressure impacting margin levels in technical services project work.

Β 

Profits at actual exchange rates were negatively impacted by Β£1m due to the strengthening of Sterling in Q3; most notably against the Euro but also against other currencies relevant to the group's operating areas. Based on current exchange rates, we expect the beneficial impact of currency movements to now be around Β£3m for the full year (Β£3m less than previously expected).

Β 

As we approach the end of our major restructuring and investment programme, central and divisional overheads are being reduced. Savings are estimated at c. Β£10m per annum from 2014 with an associated one-off cash cost of c. Β£3m. We have also decided to limit deployment of a number of centrally-developed HR and other systems which, as a result, will lead to a non-cash write-off of c. Β£7m in the fourth quarter. Consequently, restructuring costs for 2013 are now estimated at Β£60m.

Β 

Cash Flow and Funding

Β 

Cash flow in the quarter improved to Β£50.4m (Q3 2012: Β£29.3m) and is anticipated to improve further in Q4 reflecting the seasonality of the business. As noted above, we expect a material reduction in the level of restructuring costs and related capital investment in 2014.

Β 

The group took advantage of favourable market conditions to issue a 3.25% coupon €350m bond on 7Β October. The bond will be used to refinance the group's €500m bond maturing in March 2014, reducing the average cost of debt to below 4%. The carry cost associated with the bond, however, means that interest costs in Q4 will be c. Β£1.5m higher than previously anticipated. Following redemption of the March 2014 bond, annual interest costs are expected to reduce significantly - by more than Β£10m per annum at current debt levels4.

Β 

M&A

Β 

The group further expanded its global footprint in Pest Control with small transactions in North America (Vancouver, Calgary) and the Middle East (via a JV in Saudi Arabia).

Β 

Β 

Enquiries:

Β 

Investors / Analysts enquiries:

Katharine Rycroft, Head of Investor Relations Rentokil Initial plc 01293 858 166

Β 

Media enquiries:

Malcolm Padley, Corporate Communications Rentokil Initial plc 07788 978 199

Justine McIlroy, Oliver Hughes Brunswick Group 020 7404 5959

Β 

Β 

A conference call for analysts and shareholders will be held today at 09.15am, UK time. To join this call, please dial +44 (0) 20 3427 1907 (UK), +33 (0) 1 76 77 22 29 (France), +852 3002 1615 (Hong Kong), and +1 646 254 3388 (US) quoting reference code 6711238. A recording of the call will be available for 14 days on the following numbers: +44 (0)20 3427 0598 (UK), +33Β (0)1 74 20 28 00 (France), +852 3011 4669 (Hong Kong) and +1 347 366 9565 (US) quoting access code 6711238.

Β 

Β 

AER - actual exchange rates; CER - constant 2012 exchange rates

1 before amortisation and impairment of intangibles (excluding computer software), reorganisation costs and one-off items

2 before amortisation and impairment of intangibles (excluding computer software), reorganisation costs and one-off items and net interest credit from pensions

3 cash flow before interest, tax, acquisitions, disposals, foreign exchange adjustments and discontinued operations

4 compared with the average 2012 cost of debt of 5%

Β 

Correction to earnings per share published in interim results

Following the publication of our interim results on 14 August 2013 it has come to our attention that the calculation of earnings per share in note 9 should have been adjusted to exclude profit attributable to non controlling interests of Β£0.9m (HY 2012: Β£1.4m; FY 2012: Β£2.3m) and one-off items - financing of Β£nil (HY 2012: Β£nil; FY 2012: Β£31.4m). The earnings per share in respect of 2012 were correctly stated in the 2012 interim and annual reports. The table below provides the revised figures:

6 months to 30 June 2013

6 months to 30 June 2012

Year to 31 December 2012

Β 

Β£m

Β£m

Β£m

Profit from continuing operations attributable to equity holders of the Company

39.0

48.3

71.3

Adjusted profit from continuing operations attributable to equity holders of the Company

64.3

62.6

149.7

Basic earnings per share from continuing operations

2.15p

2.66p

3.92p

Basic earnings per share from continuing and discontinued operations

(0.62p)

1.82p

2.62p

Diluted earnings per share from continuing operations

2.14p

2.66p

3.91p

Diluted earnings per share from continuing and discontinued operations

(0.62p)

1.82p

2.61p

Adjusted earnings per share from continuing operations

3.54p

3.45p

8.24p

Diluted adjusted earnings per share from continuing operations

3.53p

3.45p

8.22p

Β 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

Appendix 1

Β 

Regional Analysis - continuing operations

Β 

9 months to 30 September 2013

Revenue

Adjusted operating profit

Continuing operations

Β£m

9 months to

30 September 2013

AER

Β 

Change from YTD 2012

AER

Β 

Change from YTD 2012

CER

9 months to

30 September 2013

AER

Β 

Change from YTD 2012

AER

Β 

Change from YTD 2012

CER

France

276.4

5.3%

0.8%

45.0

9.0%

4.4%

Benelux

187.7

(4.1%)

(8.3%)

37.4

(2.3%)

(6.5%)

Germany

152.0

4.6%

0.3%

33.6

4.0%

(0.3%)

Pacific

109.5

(2.8%)

0.1%

20.2

(6.0%)

(3.7%)

East

725.6

1.3%

(1.9%)

136.2

2.1%

(1.2%)

North America

261.9

49.0%

46.5%

26.1

29.9%

28.0%

UK & Ireland

138.0

0.5%

0.1%

27.7

17.9%

17.0%

Rest of World

144.6

4.0%

3.5%

30.3

2.4%

3.4%

West

544.5

20.4%

19.1%

84.1

14.9%

14.5%

Asia

79.0

8.2%

7.5%

5.3

32.5%

35.0%

Initial Facilities

402.3

(3.6%)

(3.9%)

17.4

(9.4%)

(9.4%)

Central costs

-

-

-

(59.6)

(2.4%)

(2.1%)

Total segmental

1,751.4

5.6%

3.7%

183.4

6.9%

4.3%

Reorganisation costs and one-off items

-

-

-

(35.2)

(40.2%)

(36.3%)

Amortisation of intangible assets1

-

-

-

(17.3)

(1.2%)

0.6%

Operating profit

-

-

-

130.9

1.2%

(1.2%)

Net interest payable (excluding pensions)

-

-

-

(43.4)

(24.0%)

(21.1%)

Net interest credit from pensions

-

-

-

4.4

(34.3%)

(34.3%)

Share of profit from associates (net of tax)

-

-

-

3.6

(5.3%)

13.5%

At actual exchange rates

1,751.4

5.6%

95.5

(9.0%)

Exchange

(33.4)

(2.0)

At constant exchange rates

1,718.0

3.7%

93.5

(10.4%)

Β 

1 excluding computer software

Β 

Β 

Appendix 2

Β 

Category Analysis - continuing operations

Β 

9 months to 30 September 2013

Β 

Revenue

Adjusted operating profit

Continuing operations

Β£m

9 months to

30 September 2013

AER

Β 

Change from YTD 2012

AER

Β 

Change from YTD 2012

CER

9 months to

30 September 2013

AER

Β 

Change from YTD 2012

AER

Β 

Change from YTD 2012

CER

Pest Control

478.3

18.2%

16.7%

93.5

13.3%

11.7%

Hygiene

371.6

1.3%

(0.4%)

74.4

0.4%

(0.9%)

Workwear

316.8

1.6%

(2.7%)

48.2

-

(4.4%)

Plants

95.1

(0.8%)

(2.3%)

6.9

7.8%

7.9%

Facilities Services

402.3

(3.6%)

(3.9%)

17.4

(9.4%)

(9.4%)

Other

87.3

40.6%

37.1%

(57.0)

3.1%

3.2%

At actual exchange rates

1,751.4

5.6%

183.4

6.9%

Exchange

(33.4)

(4.9)

At constant exchange rates

1,718.0

3.7%

178.5

4.3%

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSUGGCGGUPWGMM
Date   Source Headline
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update
19th Mar 202011:30 amRNSDirector Declaration
17th Mar 20201:15 pmRNSAdditional Listing
6th Mar 202012:00 pmRNSHolding(s) in Company
27th Feb 20207:05 amRNSDirectorate Change
27th Feb 20207:00 amRNSFinal Results
21st Feb 20204:00 pmRNSHolding(s) in Company
24th Dec 20191:10 pmRNSHolding(s) in Company
19th Dec 20192:40 pmRNSDirector/PDMR Shareholding
17th Dec 20195:10 pmRNSHolding(s) in Company
26th Nov 20196:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.